Brain Cancer Press Releases

Curtana Pharmaceuticals Announces New Data Confirming CT-179 Effectively Crosses Blood-Brain Barrier and Synergizes with Radiation in Pediatric Brain Cancers

Preclinical Study Reveals that CT-179 Remodels the Tumor Microenvironment – Turning "Cold" Tumors "Hot" – and Significantly Enhancing the Efficacy of Immune Checkpoint Inhibitors

Curtana Pharmaceuticals, a biotechnology company focused on improving outcomes for brain cancer patients, is proud to announce the publication of two pioneering studies in Nature Communications.